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GMC’S 2013 GUIDANCE TO DOCTORS
Importance of “acknowledging and reducing treatment
uncertainty” in appraisal and revalidation
Ian Roberts professor of epidemiology and public health 1, Brigitte Chaudhry founder 2, Iain Chalmers
coordinator 3
1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; 2RoadPeace, London, UK; 3James Lind Initiative, Oxford, UK
Last year we criticised the General Medical Council (GMC) for
omitting from its 2013 edition of Good Medical Practice its
previous view that doctors “must work with colleagues and
patients . . . to help resolve uncertainties about the effects of
treatments.”1-3 We welcome the council’s recently published
statement that it regards “Medical research [as] vital to
improving care for patients both now and in the future,”4 and
its call on doctors to consider whether they could do more to
support medical research.3 In particular, we are pleased to see
that the GMC is now urging doctors to raise patients’ awareness
of the importance of research; to look for opportunities for
themselves and patients to become involved in research studies,
and to tell patients about them so they can decide if they would
like to take part; and, lastly, to support patients who choose to
take part in studies.
We share the council’s view that such actions will reduce risks
for patients. Indeed, we believe that acknowledging uncertainties
about the effects of treatments and seeking to reduce them by
increasing the number of patients enrolled in well designed
clinical trials is a more patient centred form of “reflective
practice” than the reflection currently being endorsed by the
GMC. We urge the GMC to take the next (small) step and give
“acknowledging and reducing treatment uncertainty” the same
degree of emphasis in appraisal and revalidation as is currently
devoted to reflective practice.
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